Cystic fibrosis is not always a frameshift mutation. The disease can be caused by several different types of genetic mutations, and while frameshift mutations are one of them, the most common CF mutation, F508del, is actually an in-frame deletion. F508del accounts for roughly 70 to 80 percent of all CF-causing gene variants, and it removes a single amino acid from the CFTR protein without shifting the reading frame. So if you’re answering a genetics exam or trying to understand your own diagnosis, the short answer is: CF can involve a frameshift mutation, but most cases don’t.
What F508del Actually Is
The CFTR gene provides instructions for building a protein that moves chloride (a component of salt) in and out of cells. When this protein is faulty, mucus throughout the body becomes thick and sticky, leading to the lung and digestive problems associated with CF.
F508del is classified as an in-frame deletion. Three DNA bases are removed, which corresponds to exactly one amino acid (phenylalanine at position 508). Because three bases equal one “word” in the genetic code, removing all three doesn’t scramble the rest of the message. The protein still gets assembled to its full length, but it folds incorrectly. The cell’s quality-control system recognizes the misfolded protein and destroys most of it before it ever reaches the cell surface. The small amount that does reach the surface works poorly. This is why F508del is called a “processing mutation”: the protein is made but never properly delivered.
How Frameshift Mutations Differ
A frameshift mutation happens when one or two DNA bases are inserted or deleted, throwing off the three-letter reading pattern of the genetic code. Every “word” after the change gets misread, usually producing a premature stop signal that cuts the protein short. The result is a truncated, nonfunctional fragment rather than a full-length protein.
Several known CF-causing mutations are frameshifts. For example, 2184delA is a single-base deletion that shifts the reading frame and creates a premature stop signal. Another, 3659delC, does the same thing. A two-base deletion called c.262_263delTT shifts the frame in exon 4 and triggers a stop signal shortly downstream. In each case, the cell ends up with a severely shortened protein that cannot function as a chloride channel.
One well-studied frameshift, 3905insT, involves a single extra base inserted into exon 20. This insertion creates a premature stop signal in the same exon, and the resulting protein is missing 216 amino acids from its tail end. That’s a large enough truncation that the cell breaks down the defective protein through its normal waste-disposal system.
Why Frameshift Mutations Cause Severe Disease
Frameshift mutations in the CFTR gene fall into what researchers call Class I mutations: they prevent the cell from producing any usable protein. Cells have a built-in surveillance system that detects messenger RNA carrying premature stop signals. This system, called nonsense-mediated decay, destroys the faulty RNA before it can be used to build protein. The goal is to prevent potentially harmful protein fragments from accumulating.
In some cases, cells use a second strategy: they skip over the section of the gene containing the error during RNA processing, which can also eliminate the faulty message. Between these two mechanisms, very little (if any) CFTR protein is produced from a frameshift allele.
The clinical picture reflects this. A case study of two patients carrying the frameshift mutation 935delA found severe disease in both, including intestinal blockage at birth, pancreatic insufficiency, and early lung infection with Pseudomonas bacteria. The mutation produced a protein with only about 21 percent of its normal length. When both copies of the gene carry mutations that severely truncate the protein, the disease course tends to be more aggressive than when at least one copy produces a full-length (even if defective) protein.
Treatment Implications for Frameshift Mutations
This distinction between mutation types matters most when it comes to treatment. CFTR modulator drugs, including the highly effective triple-combination therapy approved in recent years, work by helping misfolded or malfunctioning CFTR protein do its job better. They need some protein to be present at the cell surface in order to work.
Frameshift mutations don’t give them anything to work with. Because premature stop signals prevent the cell from translating any full-length protein, there is no target for modulators to correct. Frameshift and other Class I mutations are classified as “minimal function” mutations and are associated with poor response to conventional modulator therapies. For patients carrying these mutations on both copies of their gene, no approved modulator drug is currently effective.
Researchers have explored compounds called “read-through agents” that try to coax the cell’s machinery into ignoring a premature stop signal and continuing to build the full protein. One example, gentamicin, showed some ability to increase full-length CFTR protein in lab settings, but its clinical effectiveness has been limited, partly because nonsense-mediated decay destroys so much of the messenger RNA before it ever reaches the protein-building stage. Gene therapy and RNA-based approaches aim to bypass the problem entirely by delivering a correct copy of the instructions.
The Full Picture of CF Mutation Types
More than 2,000 variants have been identified in the CFTR gene. They fall into several broad categories based on what goes wrong:
- In-frame deletions (like F508del): The protein is made to full length but folds incorrectly and gets destroyed before reaching the cell surface.
- Frameshift mutations: The reading frame is disrupted, creating a premature stop signal and a truncated, nonfunctional protein.
- Nonsense mutations: A single base change creates a stop signal directly, also producing a truncated protein. These behave similarly to frameshifts at the cellular level.
- Missense mutations: A single amino acid is swapped for another. The protein reaches the surface but doesn’t open or close properly as a channel.
- Splicing mutations: Errors in how the RNA message is edited before being used to build protein, leading to missing or extra segments.
Because CF is a recessive disease, a person needs mutations on both copies of the CFTR gene to develop symptoms. Many patients are compound heterozygotes, meaning they carry a different mutation on each copy. Someone might have F508del on one chromosome and a frameshift mutation on the other. The combination of mutation types influences disease severity and, critically, which treatments are likely to help. Patients with at least one copy of F508del or certain other mutations that produce full-length protein are generally eligible for modulator therapy, even if their other copy carries a frameshift.